Screening for cystic fibrosis-related diabetes: a systematic review.
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cystic fibrosis (CF) is an inherited disease that leads to damage to lungs, pancreas and other organs. Most people with CF die prematurely from lung disease, but survival has improved markedly over the decades and it is estimated that children born with CF now will live to an average age of 50 years. CF-related diabetes (CFRD) is due to damage to the pancreas, which, over time, loses its capacity to produce sufficient insulin. CFRD is becoming more common owing to the improved survival of people with CF. OBJECTIVES: The initial aim was to review the methods for screening for CFRD, which can be symptomless but still be causing harm. As the aim of screening and early detection is to allow earlier treatment, a second aim was to assess the effectiveness of treatments. However, during the review it became clear that there were problems with how CFRD is defined, uncertainty about when hyperglycaemia should be treated. DATA SOURCES: Details of relevant studies were obtained from the usual bibliometric databases - MEDLINE (1950-2008), EMBASE (1980-2008), The Cochrane Library (all sections), Web of Science (1970-2008). Websites of relevant bodies were searched for guidelines and reports. Conference abstracts were searched. Expert co-authors identified key papers. REVIEW METHODS: Systematic reviews of treatments and screening tests. Screening studies were data extracted if they provided sufficient data to construct 2 × 2 tables. Other screening studies were described in narrative manner. The background to CF and CFRD were described in a narrative manner, as was Chapter 2 on problems with defining CFRD. A model was constructed for cost-effectiveness analysis, but was not used because of lack of data. RESULTS: Diabetes is usually defined based on the level of blood glucose (BG) at which the risk of retinopathy occurs. For CFRD, it would be better to define it on the level at which the risk of lung disease (pulmonopathy) rises. There seems little place for treatments other than insulin, but the best insulin regimen remains to be confirmed. The best screening test may be by continuous glucose monitoring systems but further evidence is required. Screening may need to detect BG levels of > 8 mmol/l because that may be the level above which pulmonopathy starts in people with CF. LIMITATIONS: The evidence base for treatment is disappointing with few large randomised controlled trials. The key question is when treatment should start, perhaps at the post-prandial hyperglycaemia stage. Research is needed. Until that is done, we cannot be sure what we are screening for, and, therefore, which screening strategy should be used. CONCLUSIONS: The definition of CFRD should probably be based on pulmonopathy risk, rather than using the classical definition of diabetes. That implies that we should be screening for a wider range of hyperglycaemia than in other forms of diabetes, perhaps to detect BG excursions of > 8 mmol/l. Insulin treatment may need to start at lower levels than formerly accepted. FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Goldstein, D. E., Little, R. R., Lorenz, R. A., Malone, J. I., Nathan, D., Peterson, C. M., & Sacks, D. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1761 · Cited by 625
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Diabetes Prevention Program Research Group (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02043.x · Cited by 363
Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia
Moran, A., Pekow, P., Grover, P., Zorn, M., Slovis, B., Pilewski, J., Tullis, E., Liou, T. G., Allen, H., & the Cystic Fibrosis Related Diabetes Therapy Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0585 · Cited by 240
Hanefeld, M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00059-3 · Cited by 222
Riekert, K. A., Bartlett, S. J., Boyle, M. P., Krishnan, J. A., & Rand, C. S. (2007) · Chest · doi:10.1378/chest.06-2474 · Cited by 197
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Encouraging data suggest that improved screening (544,545) and aggressive insulin therapy have narrowed the gap in mortality between cystic fibrosis patients with and without diabetes, and have eliminated the sex difference in mortality (546).”
Background(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
Mayer-Davis, E. J., Kahkoska, A. R., Jefferies, C., Dabelea, D., Balde, N., Gong, C. X., Aschner, P., & Craig, M. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12773 · Cited by 682
Dunkley, A. J., Bodicoat, D. H., Greaves, C. J., Russell, C., Yates, T., Davies, M. J., & Khunti, K. (2014) · Diabetes Care · doi:10.2337/dc13-2195 · Cited by 542
Turck, D., Braegger, C. P., Colombo, C., Declercq, D., Morton, A., Pancheva, R., Robberecht, E., Stern, M., Strandvik, B., Wolfe, S., et al. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.03.004 · Cited by 526
Metadata
- Authors
- Waugh, N., Royle, P., Craigie, I., Ho, V, Pandit, L., Ewings, P., Adler, A., Helms, P., & Sheldon, C.
- Venue
- Health Technology Assessment
- Published
- 2012-05
- Volume
- 16
- Issue
- 24
- Pages
- iii-iv, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2039474311
- Cited by
- 63
- References
- 8
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for cystic fibrosis-related diabetes: a systematic review. https://app.cochat.ai/papers/10.3310/hta16240
- The paper
- Waugh, N., Royle, P., Craigie, I., Ho, V, Pandit, L., Ewings, P., Adler, A., Helms, P., & Sheldon, C. (2012). Screening for cystic fibrosis-related diabetes: a systematic review. Health Technology Assessment. https://doi.org/10.3310/hta16240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.